Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan

NCT04319198 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04319198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04319198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Completed
Start date
August 4, 2020
Completion date
October 18, 2024
Enrollment
25 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumors